Interferon-induced pulmonary hypertension: An update

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 5, 2016, Pages 415-420

  Savale, Laurent ^a,b,c   Chaumais, Marie Camille ^a,c,d   O'Connell, Caroline ^a,b,c   Humbert, Marc ^a,b,c   Sitbon, Olivier ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Interferon; pulmonary hypertension; side effect

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; ANTIVIRUS AGENT;

DRUG EXPOSURE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG VASCULAR RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; CHEMICALLY INDUCED; COMPLICATION; HYPERTENSION, PULMONARY;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; HYPERTENSION, PULMONARY; INTERFERON-ALPHA; INTERFERON-BETA; RISK FACTORS;

EID: 84978043651     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000307     Document Type: Review

References (30)

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl): D34-D41.
2. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46:903-975.
3. Kramers C, deMulder PH, Barth JD, Wagener DJ. Acute right ventricular heart failure in a patient with renal cell carcinoma after interferon therapy. Neth J Med 1993; 42:65-68.
4. Fruehauf S, Steiger S, Topaly J, Ho AD. Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 2001; 80:308-310.
5. Jochmann N, Kiecker F, Borges AC, et al. Long-term therapy of interferonalpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 2005; 3:26.
6. Dhillon S, Kaker A, Dosanjh A, et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 2010; 55:1785-1790.
7. Ledinek AH, Jazbec SS, Drinovec I, Rot U. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Mult Scler 2009; 15:885-886.
8. Savale L, Sattler C, Gunther S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2014; 44:1627-1634.
9. Caravita S, Secchi MB, Wu SC, et al. Sildenafil therapy for interferon-beta-1ainduced pulmonary arterial hypertension: a case report. Cardiology 2011; 120:187-189.
10. Govern EM, Judge EP, Kavanagh E, et al. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity Mult Scler Relat Disord 2015; 4:284-286.
11. Gibbons E, Promislow S, Davies RA, et al. Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Can Respir J 2015; 22:263-265.
12. Prella M, Yerly P, Nicod LP, Aubert JD. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2015; 46:1849-1851.
13. Ko T, Hatano M, Nitta D, et al. A case of interferon-alpha-induced pulmonary arterial hypertension after living donor liver transplantation. Heart Vessels 2015. [Epub ahead of print]
14. Fok A, Williams T, McLean CA, Butler E. Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients. Mult Scler 2015. [Epub ahead of print]
15. Anderson RD, Thompson A, Burns AT. Pulmonary arterial hypertension associated with the use of interferon therapy for chronic hepatitis C infection complicated by extrinsic left main coronary artery compression. Intern Med J 2014; 44:1027-1030.
16. Savale L, Chaumais MC, Sitbon O, Humbert M. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2015; 46:1851-1853.
17. Piroddi IM, Barlascini C, Nicolini A. Severe respiratory failure due to interferon beta-related pulmonary hypertension. Am J Ther 2015. [Epub ahead of print]
18. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 2014; 114:677-688.
19. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125:2128-2137.
20. Savale L, Chaumais MC, Cottin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40:1164-1172.
21. Montani D, Seferian A, Savale L, et al. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 2013; 22:244-250.
22. Hanaoka M, Kubo K, Hayano T, et al. Interferon-alpha elevates pulmonary blood pressure in sheep-the role of thromboxane cascade. Eur J Pharmacol 1999; 370:145-151.
23. Badiger R, Mitchell JA, Gashaw H, et al. Effect of different interferonalpha 2 preparations on IP10 and ET-1 release from human lung cells. PLoS One 2012; 7:e46779.
24. Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010; 62:589-598.
25. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42:299-305.
26. Eloranta ML, Franck-Larsson K, Lovgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69:1396-1402.
27. Zagury D, Lachgar A, Chams V, et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95:3851-3856.
28. Lehmann C, Lafferty M, Garzino-Demo A, et al. Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One 2010; 5:e11110.
29. Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008; 14:1077-1087.
30. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2015; 373:1418-1428.